<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25408" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Genetics, Mutagenesis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Durland</surname>
            <given-names>Justin</given-names>
          </name>
          <aff>Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmadian-Moghadam</surname>
            <given-names>Hamid</given-names>
          </name>
          <aff>Tehran University of Medical Science</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Justin Durland declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hamid Ahmadian-Moghadam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25408.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Mutagenesis is the process of an organism's deoxyribonucleic acids (DNA) change, resulting in a gene mutation. A mutation is a permanent&#x000a0;and heritable change in genetic material, which can result in altered protein function and phenotypic changes. DNA consists of nucleotides that contain a phosphate backbone, a deoxyribose sugar, and&#x000a0;1 of&#x000a0;4 nitrogen-containing bases (adenine [A], guanine [G], cytosine [C], and thymine [T]).&#x000a0;DNA mutagenesis occurs spontaneously in nature or as a result of mutagens (agents&#x000a0;predisposing to alter DNA). Furthermore, molecular genetic techniques, such as polymerase chain reaction (PCR), have revolutionized how mutations are obtained and studied. Mutagenesis is the driving force of evolution; however, it can also lead to cancers and heritable diseases (See <bold>Image.</bold>&#x000a0;Genome Editing).<xref ref-type="bibr" rid="article-25408.r1">[1]</xref>&#x000a0;</p>
        <p>Single base-pair substitutions are the most common cause of human pathology. An&#x000a0;example is&#x000a0;sickle cell disease, where a single base-pair mutation results in substituting glutamate to valine amino acid. Otherwise, human disease results from various insertions, deletions, duplications, inversions, expansions, fusions, and complex rearrangements. For example, a CGG repeat expansion in the FRM1 gene causes fragile X syndrome, while a fusion protein BCR-ABL results in chronic myeloid leukemia (CML).<xref ref-type="bibr" rid="article-25408.r2">[2]</xref><xref ref-type="bibr" rid="article-25408.r3">[3]</xref></p>
      </sec>
      <sec id="article-25408.s2" sec-type="Biochemical">
        <title>Biochemical</title>
        <p>It is noteworthy that not all DNA mutations have an impact on protein synthesis or function. There are various mutations, such as silent, missense, nonsense, and frameshifts.</p>
        <p>A silent mutation is a nucleotide substitution that codes for the same amino acid; therefore, there is no change in the amino acid sequence or protein function.</p>
        <p>A missense mutation occurs when a nucleotide substitution changes an amino acid. Missense mutations have variable effects but can lead to a decreased or altered protein function (eg, sickle cell disease).<xref ref-type="bibr" rid="article-25408.r4">[4]</xref>&#x000a0;</p>
        <p>A nonsense mutation is when a nucleotide substitution results in a new stop codon, which includes UGA, UAA, and UAG (remember the mnemonic "U Go Away, U Are Away, and U Are Gone," respectively). These protein products are truncated and frequently nonfunctional (eg, cystic fibrosis).<xref ref-type="bibr" rid="article-25408.r5">[5]</xref>&#x000a0;</p>
        <p>A frameshift mutation occurs by adding or deleting nucleotides not divisible by 3, resulting in the misreading of the downstream nucleotides. These proteins may be shorter or longer, and protein function may be disrupted or altered (eg, Duchenne muscular dystrophy).<xref ref-type="bibr" rid="article-25408.r6">[6]</xref>&#x000a0;</p>
        <p>Other types of mutations exist outside of the coding sequence. These include splice site, promoter or enhancer sequence, and termination site mutations.&#x000a0;For example, in some forms of B-thalassemia, a mutated splice site uses cryptic splice locations, causing impaired B-globin synthesis.<xref ref-type="bibr" rid="article-25408.r7">[7]</xref></p>
      </sec>
      <sec id="article-25408.s3" sec-type="Function">
        <title>Function</title>
        <p>Mutagenesis is the driving force behind evolution and genetic variation results from mutations. Any change in genetic information may result in advantageous or disadvantageous phenotypic characteristics that impact an organism's fitness. When a mutation results in a higher&#x000a0;fitness, natural selection favors these phenotypes, and these traits are more likely to be passed to offspring.<xref ref-type="bibr" rid="article-25408.r8">[8]</xref></p>
      </sec>
      <sec id="article-25408.s4" sec-type="Mechanism">
        <title>Mechanism</title>
        <p>Mutagenesis occurs due to DNA replication errors, damage, and lab techniques. Here, we break mutagenesis down into endogenous and exogenous causes.</p>
        <p>
<bold>Endogenous</bold>
</p>
        <list list-type="order">
          <list-item>
            <p><bold>Errors in DNA replication</bold>:&#x000a0;Our body possesses high and low-fidelity DNA polymerases. Although the error rate is minimal, high-fidelity polymerases and mismatch repair (MMR) mechanisms still make 1 in 10^6 to 10^8 base substitution per cell per generation. Furthermore, some errors occur due to replication slippage at repetitive sequences, which can lead to insertions and deletions. A mutation results if these errors are not repaired before the next round of DNA replication.<xref ref-type="bibr" rid="article-25408.r9">[9]</xref><xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Errors in DNA repair mechanisms</bold>:&#x000a0;The DNA damage response (DDR) is a group of mechanisms that sense DNA &#x02014;errors and promote repair. Errors in repair or mutations affecting the DDR network cause different cancers. There are multiple DNA repair mechanisms, including MMR, base excision repair (BER), nucleotide excision repair (NER), translesion synthesis (TLS), homologous recombination (HR), and nonhomologous end-joining (NHEJ) pathways. A cell is predisposed to DNA damage if these repair mechanisms disappear. For example, xeroderma pigmentosum (a rare autosomal recessive skin disorder that makes a person highly prone to developing skin cancer) is caused by a mutation in the NER pathway, resulting in a build-up of UV-associated damage. The TLS repair system and NHEJ are of interest to endogenous mutagenesis. During DNA replication, high-fidelity polymerases have difficulty passing damaged bases (eg, pyrimidine dimers or crosslinked DNA), which stalls DNA replication. Failure to restart replication can result in double-stranded breaks, chromosomal rearrangements, and cell death. Therefore, it is often beneficial to circumvent these replicative arrests to promote cell survival. One mechanism to accomplish this is the TLS system. TLS involves DNA polymerases with larger active sites that allow them to tolerate and bypass DNA lesions. However, it comes at the expense of lower replication fidelity and high error rates, resulting in a greater likelihood of base substitutions.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref>&#x000a0;Otherwise, NHEJ is a repair mechanism for double-stranded DNA breaks. It brings&#x000a0;2 ends of DNA fragments together and doesn't require homologous sequences. Therefore, this can result in deletions and insertions.<xref ref-type="bibr" rid="article-25408.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Spontaneous base deamination</bold>:&#x000a0;Base deamination is when a nucleotide base loses an amine group, effectively changing the nucleotide. The following are major deamination reactions: cytosine to uracil (U), adenine to hypoxanthine, guanine to xanthine, and 5-methyl cytosine (5mC) to thymine. If these alterations are not repaired, there can be a change in the DNA sequence. For example, if cytosine deaminates to uracils, there&#x000a0;are new A:T mutations in&#x000a0;2 replication events. This G:C to A:T transition accounts for 33% of the single-site mutations resulting in human hereditary diseases.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Oxidative DNA damage</bold>: Reactive oxygen species (ROS) are a byproduct of the electron transport chain (ETC) and other cellular processes in normal cell physiology. ROS serves essential cellular roles, including redox signaling and immune defense. However, in high quantities, ROS damages a cell and its DNA. There have been 100 different oxidative base lesions and 2-deoxyribose modifications described. One example is the oxidation of carbon #8 of guanine, forming 8-oxoguanine (8-OG). 8-OG incorrectly pairs with adenine (instead of cytosine), resulting in a G:C to A:T transition. Excess ROS are known to be associated with many diseases, including Alzheimer's disease, cancer, and heart failure.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Base methylation</bold>:&#x000a0;S-adenosylmethionine (SAM) is used as a methyl donor during physiologic DNA methylation. At a concentration of 4x10^-5M, SAM can generate over 4,000 methylated base changes per cell per day. The significance of this can be depicted in the methylated products&#x000a0;O6-methylguanine and&#x000a0;O4-methylamine. These highly mutagenic products result in G:C to A:T and T:A to C:G transition mutations.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref><xref ref-type="bibr" rid="article-25408.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Abasic sites </bold>(ie, apurinic and apyrimidinic sites): Approximately 10,000 abasic sites are made daily by spontaneous hydrolysis or DNA glycosylase cleavage. Abasic sites are unstable and commonly removed by endonucleases. In other cases, they are repaired by TLS polymerases. If these damage sites are not corrected, they may result in mutagenesis.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref><xref ref-type="bibr" rid="article-25408.r13">[13]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Exogenous</bold>
</p>
        <list list-type="order">
          <list-item>
            <p><bold>Ionizing radiation (IR)</bold>:&#x000a0;IR comes from the soil, radon, medical devices, and cosmic radiation, among others. It can damage DNA directly (eg, DNA strand breaks) or indirectly (eg, radiolysis of water molecules producing ROS). Ionizing radiation can generate a range of nucleotide base lesions, similar to that discussed for ROS, resulting in mutagenesis.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Ultraviolet (UV) radiation</bold>:&#x000a0;UV light falls between 100&#x000a0;to 400 nm, with the most harmful radiation at lower wavelengths&#x02014;UV light damages DNA through direct and indirect energy transfer (to nearby molecules. The&#x000a0;2 main products of UV damage are pyrimidine dimers and pyrimidine pyrimidone photoproducts. These byproducts distort the DNA helix, requiring the NER system or the error-prone TLS polymerases to bypass them. Pyrimidine dimers cause C:G to T:A, T:A to C:G, and tandem CC to TT transition mutations.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Alkylating agents &#x00026; Aromatic amines</bold>:&#x000a0;Alkylating agents (eg, nitrogen mustard gas, methyl methanesulfonate [MMS], ethyl methanesulfonate [EMS], N-ethyl-N-nitrosourea [ENU]) have a high affinity for nitrogens on nucleotide bases, mainly N3 of adenine and N7 of guanine. MMS, for example, reacts with adenine and guanine to produce N3-methyladenine and N7-methylguanine, respectively. These methyl products are susceptible to N-glycosidic bond cleavage that can create abasic sites. Aromatic amines (eg, 2-aminofluorene, previously used in insecticides) are metabolized by the CYP450 system and converted into alkylating agents. These products primarily cause lesions to the C8 position of guanine. C8-guanine lesions are known to give rise to base substitutions and frameshift mutations.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Polycyclic aromatic hydrocarbon (PAH)</bold>:&#x000a0;PAHs (eg, dibenzo[a,l]pyrene, naphthalene, anthracene, and pyrene) are carbon compounds with&#x000a0;2 or more aromatic rings. They are commonly present in tobacco smoke, automobile exhaust, charred food, and combustion products of fossil fuels and organic matter. The CYP450 enzymes convert PAHs into reactive DNA intermediates that intercalate into DNA, ultimately forming a DNA adduct (a segment of DNA bound to a cancer-causing chemical). This results in DNA damage and, thus, can cause mutagenesis.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Crosslinking</bold>:&#x000a0;Crosslinking occurs when&#x000a0;2 nucleotides form a covalent link. Agents commonly associated with crosslinking include cyclophosphamide, cisplatin, and psoralens. Interstrand crosslinking blocks DNA replication, and this requires repair or bypassing. TLS is one of these repair mechanisms and is associated with high substitution rates.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref><xref ref-type="bibr" rid="article-25408.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Insertional mutagenesis</bold>:&#x000a0;This is the process by which exogenous DNA integrates into host DNA. Insertional mutagenesis can be natural, mediated by transposons or viruses, or accomplished in a laboratory. Given there is an addition of nucleotides, insertional mutagenesis commonly results in frameshift mutations.<xref ref-type="bibr" rid="article-25408.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Other toxins</bold>:&#x000a0;Aflatoxin is a naturally occurring toxin from <italic toggle="yes">Aspergillus</italic>. The CYP450 system metabolizes aflatoxin into an active form that adducts with N7 of guanine, which results in depurination. Aflatoxin is a well-established liver carcinogen that is associated with hepatocellular carcinoma. N-nitrosamines are organic compounds commonly found in tobacco smoke, preserved meats, and the environment. The CYP450 system metabolizes them to form DNA alkylating agents. N-nitrosamines have been implicated in nasopharyngeal, esophageal, and gastric.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref><xref ref-type="bibr" rid="article-25408.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Laboratory techniques</bold>: Different laboratory techniques, including PCR, non-PCR, and gene-editing tools, induce mutagenesis. These are discussed further in the "Testing/Methods" section below.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25408.s5" sec-type="Testing">
        <title>Testing</title>
        <p>Mutagenesis is a technique used in molecular biology to create mutant genes, proteins, and organisms. Two primary mutagenesis techniques are site-directed mutagenesis (SDM) and random-and-extensive mutagenesis (REM). These methods are accomplished mainly by primarily conducted (PCR) and non-polymerase chain reactions (non-PCR). Other mutagenesis performing/Cas9 technology methods are TALENs (transcription activator-like effector nucleases) and Zinc-Finger Nucleases (ZFN).</p>
        <p>
<bold>Site-directed Mutagenesis</bold>
</p>
        <p>SDM&#x000a0;is a technique where DNA can be modified at a specific nucleotide location, causing a predetermined amino acid change. These substitution&#x000a0;mutations can result in drastic changes in protein conformation and function. This technique requires (1) a DNA template with a target gene, (2) knowledge of the target gene's nucleotide sequence, and (3) a short primer (commonly 20&#x000a0;to 30 base pairs) complementary to the target sequence that is modified to contain a mismatched nucleotide (typically 1&#x000a0;to 3 base pairs that cause an amino acid change). The general procedure for SDM is the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Step 1: Separation&#x000a0;of the&#x000a0;2 strands of template DNA. This can be accomplished by heat or an alkali solution.</p>
          </list-item>
          <list-item>
            <p>Step 2: Addition of the modified DNA primer. Once the DNA primer anneals with a single strand, a DNA polymerase replicates the strand.</p>
          </list-item>
          <list-item>
            <p>Step 3: The second round of replication yields a mutant DNA strand that can be used to synthesize a modified protein.</p>
          </list-item>
        </list>
        <p>
<bold>Techniques for Performing SDM</bold>
</p>
        <p>PCR and non-PCR techniques are in vitro methods for performing SDM. In vitro synthesis has&#x000a0;4 essential components: DNA template, modified primers, deoxyribonucleic nucleoside triphosphates (dNTPs [ie, dATP, dCTP, dGTP, dTTP]), and DNA polymerase (thermostable or thermolabile). The polymerase&#x000a0;chain reaction technique<bold>&#x000a0;</bold>utilizes thermostable DNA polymerases (eg, Taq, Pfu, and Vent), at least&#x000a0;2 primers, and multiple heating and cooling cycles (average 30 cycles). Each cycle has&#x000a0;3 phases: denaturation (approximately 95 degrees Celsius), annealing (about 55 degrees Celsius), and extension (about 72 degrees Celsius). The denaturation phase separates the template DNA molecule into&#x000a0;2 single-stranded molecules. The&#x000a0;annealing phase is when the modified primer base pairs at the sequence of interest. Lastly, the extension phase extends the annealed primers according to the template strand.&#x000a0;The advantage of PCR is that it works more favorably&#x000a0;with different DNA templates (ie, single or double-stranded DNA and GC-rich regions) and produces millions of copies of a target gene. The disadvantage is there is less sequence fidelity (ie, thermostable polymerases are more error-prone than thermolabile polymerases). The&#x000a0;non-polymerase chain reaction technique<bold>&#x000a0;</bold>utilizes thermolabile DNA polymerases,&#x000a0;1 primer, and a constant reaction temperature (eg, 37 degrees Celsius). The DNA template is denatured with an alkali solution or heat in this strategy. The template is annealed with the modified primer, and DNA synthesis occurs at 37 degrees Celsius. Though single or double-stranded DNA templates can be used, more favorable outcomes occur if a single-stranded DNA template is used (this increases the success of annealing). This process produces a hybrid DNA molecule (ie,&#x000a0;1 template strand and&#x000a0;1 newly synthesized mutant strand), which can be transformed or infected into <italic toggle="yes">E. coli</italic>. Once in <italic toggle="yes">E.coli</italic>, the mutant DNA and wild-type DNA can be segregated. Non-PCR has greater sequence fidelity than the PCR method; however, only 1 DNA strand is generated (rather than millions).<xref ref-type="bibr" rid="article-25408.r17">[17]</xref></p>
        <p>
<bold>Screening for Desired Mutants in SDM</bold>
</p>
        <p>There are different methods for selecting and screening for desired mutants. One of the PCR approaches is to use plasmids grown in <italic toggle="yes">E. coli</italic>&#x000a0;&#x000a0;dam methylated) and contain a gene for antibiotic resistance.&#x000a0;As discussed, modified forward and reverse primers are extended around plasmid DNA, creating copies of the template with the inserted mutations. Since the original parental template strand is methylated, a restriction endonuclease Dpn I - specific for methylated and hemimethylated DNA - digests this DN, A leaving only the mutant plasmid, which is further amplified. The plasmid is transformed into E.coli, and bacteria are grown on media that contain the appropriate antibiotic for the plasmid. One can then pick single colonies and grow them overnight to isolate the mutant plasmid DNA. Please refer to the article by Bachman for a more detailed review.<xref ref-type="bibr" rid="article-25408.r18">[18]</xref>&#x000a0;Since there is the possibility of random mutations in PCR and non-PCR methods, sequencing should be performed to verify the desired mutation was made.&#x000a0;DNA sequencing technology (eg, Sanger sequencing or next-generation sequencing) can be utilized to determine nucleotide sequences.<xref ref-type="bibr" rid="article-25408.r19">[19]</xref></p>
        <p>
<bold>Random and Extensive Mutagenesis</bold>
</p>
        <p>REM is a useful approach when many mutations are desired; however, there is less control over the resulting modifications. This technique has helped map out critical residues of proteins (eg, EcoRV restriction endonuclease). REM can be accomplished through different methods:</p>
        <list list-type="bullet">
          <list-item>
            <p>Primers randomly produced with mismatched bases. This technique synthesizes a set of mutagenic primers with&#x000a0;3 mismatched bases at a single base position in the same reaction. These sets of primers are then used to synthesize mutant DNA with&#x000a0;3 different mutations at the same base position. Other than this, a primer can be synthesized using an ambiguous base (eg, deoxyinosine), capable of base-pairing with varying dNTPs. In theory, there is a 75% probability a wrong base pairs with this ambiguous base, which generates mutations in subsequent rounds of replication.</p>
          </list-item>
          <list-item>
            <p>Erroneous PCR. Taq DNA polymerase typically has lower fidelity than other polymerases (eg, Pfu and Vent). Furthermore, altering external conditions, such as buffer composition (eg, high pH or high magnesium concentration), can affect the frequency of errors. Under various combinations of external conditions, the error rate of Taq PCR can be increased to 1 in 150 base pairs from 1 in 633.</p>
          </list-item>
          <list-item>
            <p>Use of ambiguous base analogs (eg, deoxyinosine). As already stated, deoxyinosine triphosphate (dI) can base pair with different dNTPs. In a reaction that contains dI and adjusted dNTPs concentrations (eg, typical levels of&#x000a0;3 dNTPs and low levels of the fourth dNTP), a dI is likely to be incorporated into the newly synthesized sequence. Theoretically, there is a 75% chance that a wrong base pairs with a dI during subsequent replication events. This technique can result in 1 in 250 base pair mutation rates.<xref ref-type="bibr" rid="article-25408.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Use of mutagenic agents. A classic method for causing widespread random mutations is exposing a cell or organism to a mutagen (eg, ENU).<xref ref-type="bibr" rid="article-25408.r20">[20]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Insertions and Deletions</bold>
</p>
        <p>PCR is effective at producing insertions&#x000a0;or deletions. Small insertions or deletions (less than&#x000a0;10 base pairs) can occur by utilizing the modified primer design described above. Large&#x000a0;deletions can occur by joining&#x000a0;2 PCR-amplified fragments, which omit&#x000a0;a portion of a DNA fragment. Large insertions can occur using megaprimers or overlap-extension PCR.<xref ref-type="bibr" rid="article-25408.r17">[17]</xref></p>
        <p>
<bold>CRISPR-Cas9</bold>
</p>
        <p>This genome-editing technology is derived from bacterial defenses against viruses and foreign plasmids. It has&#x000a0;2 vital components: a&#x000a0;guide RNA (gRNA) that binds in a complementary way to a target DNA sequence and an&#x000a0;endonuclease (Cas9) that causes a dsDNA break that requires repair.&#x000a0;Cas9-induced site-specific dsDNA breaks induce endogenous cell repair mechanisms, which can be exploited to modify DNA. The error-prone nonhomologous end-joining (NHEJ) can rapidly ligate DNA breaks; however, it may generate small insertions and deletions that can cause frameshift mutations. Alternatively, dsDNA breaks can be repaired by homology-directed repair (HDR), which can insert exogenous DNA and introduce precise genome editing.<xref ref-type="bibr" rid="article-25408.r21">[21]</xref></p>
        <p>
<bold>TALENS vs. Zinc Finger Nucleases</bold>
</p>
        <p>TALENs and&#x000a0;ZFN are gene-editing tools with similar principles; however, they have different underlying designs. They both are proteins that consist of DNA binding domains (ie, TALE proteins vs. zinc fingers domains) and DNA cleavage domains (eg, Fok1). DNA specificity resides in the TALE proteins and the zinc finger domains. For cleavage to occur, the restriction enzyme must dimerize; therefore, at least&#x000a0;2 proteins are needed per target DNA. A double-stranded DNA break is made once dimerization occurs at a target location. Similar to CRISPR, this is repaired by NHEJ (with the possibility of insertions and deletions) or homologous recombination (where exogenous DNA can be added). A key difference between TALENs and ZFN is that TALE proteins recognize a single base, while zinc finger domains recognize 3&#x000a0;or 4 bases. Given that zinc fingers must recognize multiple bases, it may reduce DNA specificity compared to TALE proteins.<xref ref-type="bibr" rid="article-25408.r22">[22]</xref><xref ref-type="bibr" rid="article-25408.r23">[23]</xref></p>
      </sec>
      <sec id="article-25408.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Mutagenesis has multiple implications in clinical medicine. This&#x000a0;topic&#x000a0;discusses a few, including carcinogenesis, heritable diseases, microorganism resistance, large-scale mutagenic projects, and precision medicine.</p>
        <p>Carcinogenesis (i.e., tumorigenesis or oncogenesis) is when a cell begins to divide uncontrollably. Mutations of oncogenes (which promote cell growth), tumor suppressor genes (which inhibit cell growth), or cell-cycle genes (which regulate the cell cycle) can generate a clonal cell population with highly proliferative properties, leading to cancer.<xref ref-type="bibr" rid="article-25408.r24">[24]</xref>&#x000a0;Approximately two-thirds of cancer driver mutations are attributable to spontaneous mutagenesis that occurs during normal DNA replication.<xref ref-type="bibr" rid="article-25408.r25">[25]</xref>&#x000a0;Furthermore, multiple agents (such as those described in the "mechanism" section) are known to be associated with carcinogenesis. Tobacco contains DNA methylating agents, alkylating agents, polycyclic aromatic hydrocarbons, and N-nitrosamines. Smoking tobacco is proven to increase the risk of a multitude of cancers, including lung, colorectal, head and neck, and lower urinary tract cancers. Tobacco accounts for 16% of all cancer diagnoses and approximately one-third of all cancer deaths in the US. This highlights why counseling on smoking cessation and other preventative health measures becomes so important.<xref ref-type="bibr" rid="article-25408.r10">[10]</xref><xref ref-type="bibr" rid="article-25408.r24">[24]</xref><xref ref-type="bibr" rid="article-25408.r26">[26]</xref>&#x000a0;</p>
        <p>Ionizing radiation (IR), as a consequence of atomic radiation (eg, Chernobyl) or iatrogenic causes, is associated with papillary thyroid carcinoma (PTC), among others.&#x000a0;In PTC, IR increases the rate of DNA rearrangements that cause a permanently active promotor region of <italic toggle="yes">ret</italic>, a&#x000a0;tyrosine kinase. This has been associated with the pathogenesis of PTC.&#x000a0;Applying this knowledge, anti-promoter agents may one day be a method for future PT therapy.<xref ref-type="bibr" rid="article-25408.r27">[27]</xref> Interestingly, some chemotherapeutic drugs used to combat cancers - in particular, cisplatin, cyclophosphamide, and etoposide - are themselves carcinogenic. These drugs have been implicated in the development of tumor resistance&#x000a0;and subsequent cancer development. Therefore, care should be taken when choosing treatment regimens, especially in childhood cancers.<xref ref-type="bibr" rid="article-25408.r28">[28]</xref>&#x000a0;</p>
        <p>Heritable diseases originate in mutagenesis, as these are permanent DNA changes passed to offspring. Some examples of hereditary diseases include sickle cell disease, Tay-Sachs disease, cystic fibrosis, Huntington disease, Duchenne muscular dystrophy, and hemophilia, among many others. A well-studied example is sickle cell anemia. This autosomal recessive disease results from a missense mutation in the B-globin gene (ie, a point mutation resulting in a glutamic acid to valine substitution). Research shows this mutation created an adaptive advantage in heterozygote carriers in malaria-endemic areas.<xref ref-type="bibr" rid="article-25408.r29">[29]</xref>&#x000a0;However, homozygous inheritance has a poor prognosis due to increased risk for anemia, infection, stroke, and organ damage.<xref ref-type="bibr" rid="article-25408.r30">[30]</xref></p>
        <p>Drug resistance in microorganisms is a result of mutagenesis. Multidrug-resistant (MDR) organisms are associated with increased antibiotic use. MDR organisms have increased mortality rates, and it is estimated that by 2050, there might be 300 million premature deaths worldwide due to MDR organisms. This highlights the need to practice effective antimicrobial stewardship to slow the development of MDR organisms.<xref ref-type="bibr" rid="article-25408.r31">[31]</xref>&#x000a0;An interesting example of drug resistance can occur in the treatment of Chagas disease. Benznidazole is a front-line pro-drug used in Chagas treatment. New evidence suggests that <italic toggle="yes">Trypanosoma cruzi</italic> may process this drug into metabolites that cause whole-genome mutations. Therefore, this may be a reason for treatment failure and the development of drug-resistant parasites. This can even lead to resistance to different classes of drugs, like posaconazole, used in combination therapy of <italic toggle="yes">Trypanosoma cruzi</italic>. Therefore, vigilance is required when using benznidazole in combination therapy.<xref ref-type="bibr" rid="article-25408.r32">[32]</xref></p>
        <p>Large-scale mutagenesis techniques can map functional amino acid residues that affect particular phenotypes. For example, a mouse study on the Golgi protein GMAP-210 showed that gene alteration caused a phenotype that resembled human achondrogenesis type 1A. This helped lead to the discovery of a similar mutation found in humans.<xref ref-type="bibr" rid="article-25408.r33">[33]</xref></p>
        <p>Lastly, precision medicine (PM) is a concept where disease treatment is based on knowing an individual's genome abnormalities, which became relevant as whole-genome sequencing became&#x000a0;more accessible. PM depends on new therapeutic strategies, drug development, and gene-oriented treatment.<xref ref-type="bibr" rid="article-25408.r34">[34]</xref>&#x000a0;For example, gene-targeted techniques like CRISPR/Cas9 and TALENs may one day have clinical use. CRISPR is being investigated to treat single-gene mutations (eg, DMD, cystic fibrosis), HIV, and cancers.<xref ref-type="bibr" rid="article-25408.r35">[35]</xref>&#x000a0;PM still has multiple challenges, such as validating functional mechanisms of mutated gene expression.<xref ref-type="bibr" rid="article-25408.r34">[34]</xref>&#x000a0;However, PM may one day have an essential impact on disease cures.</p>
      </sec>
      <sec id="article-25408.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25408&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25408">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25408/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25408">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-25408.s8">
        <fig id="article-25408.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Genome Editing. A Schematic of using meganuclease, zinc finger nuclease, TALEN, and CRISPR nucleases for genome editing. The different generations of genome editing and DNA repair pathways are used to modify target DNA. Mazhar Adli, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0">Public Domain</ext-link>, via Wikimedia Commons</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="MEGANUCL-ZFN-TALEN-CRISPR" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-25408.s9">
        <title>References</title>
        <ref id="article-25408.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vijg</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Somatic Mutagenesis in Mammals and Its Implications for Human Disease and Aging.</article-title>
            <source>Annu Rev Genet</source>
            <year>2018</year>
            <month>Nov</month>
            <day>23</day>
            <volume>52</volume>
            <fpage>397</fpage>
            <page-range>397-419</page-range>
            <pub-id pub-id-type="pmid">30212236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Human gene mutation in pathology and evolution.</article-title>
            <source>J Inherit Metab Dis</source>
            <year>2002</year>
            <month>May</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>157</fpage>
            <page-range>157-82</page-range>
            <pub-id pub-id-type="pmid">12137225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ayatollahi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Keramati</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Shirdel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kooshyar</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Raiszadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shakeri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sadeghian</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran.</article-title>
            <source>Caspian J Intern Med</source>
            <year>2018</year>
            <season>Winter</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-70</page-range>
            <pub-id pub-id-type="pmid">29387322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ribeil</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hacein-Bey-Abina</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Payen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Semeraro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Magrin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Caccavelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Neven</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bourget</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>El Nemer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bartolucci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Puy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meritet</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Grevent</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Beuzard</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chr&#x000e9;tien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lefebvre</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Negre</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Veres</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Soni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Montalembert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blanche</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Leboulch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cavazzana</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gene Therapy in a Patient with Sickle Cell Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Mar</month>
            <day>02</day>
            <volume>376</volume>
            <issue>9</issue>
            <fpage>848</fpage>
            <page-range>848-855</page-range>
            <pub-id pub-id-type="pmid">28249145</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McHugh</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Steele</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Valerio</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Miron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>LePage</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Conlon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cotton</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Drumm</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hodges</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e0199573</fpage>
            <pub-id pub-id-type="pmid">29924856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabebordbar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>JKW</given-names>
              </name>
              <name>
                <surname>Chew</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Widrick</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Maesner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ran</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Cong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vandenberghe</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Church</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Wagers</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>In vivo gene editing in dystrophic mouse muscle and muscle stem cells.</article-title>
            <source>Science</source>
            <year>2016</year>
            <month>Jan</month>
            <day>22</day>
            <volume>351</volume>
            <issue>6271</issue>
            <fpage>407</fpage>
            <page-range>407-411</page-range>
            <pub-id pub-id-type="pmid">26721686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atweh</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Anagnou</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Shearin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Forget</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Kaufman</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Beta-thalassemia resulting from a single nucleotide substitution in an acceptor splice site.</article-title>
            <source>Nucleic Acids Res</source>
            <year>1985</year>
            <month>Feb</month>
            <day>11</day>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>777</fpage>
            <page-range>777-90</page-range>
            <pub-id pub-id-type="pmid">2987809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lenski</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>What is adaptation by natural selection? Perspectives of an experimental microbiologist.</article-title>
            <source>PLoS Genet</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>e1006668</fpage>
            <pub-id pub-id-type="pmid">28426692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunkel</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Evolving views of DNA replication (in)fidelity.</article-title>
            <source>Cold Spring Harb Symp Quant Biol</source>
            <year>2009</year>
            <volume>74</volume>
            <fpage>91</fpage>
            <page-range>91-101</page-range>
            <pub-id pub-id-type="pmid">19903750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatterjee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of DNA damage, repair, and mutagenesis.</article-title>
            <source>Environ Mol Mutagen</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>235</fpage>
            <page-range>235-263</page-range>
            <pub-id pub-id-type="pmid">28485537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heidenreich</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Novotny</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kneidinger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Holzmann</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wintersberger</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Non-homologous end joining as an important mutagenic process in cell cycle-arrested cells.</article-title>
            <source>EMBO J</source>
            <year>2003</year>
            <month>May</month>
            <day>01</day>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>2274</fpage>
            <page-range>2274-83</page-range>
            <pub-id pub-id-type="pmid">12727893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Bont</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>van Larebeke</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Endogenous DNA damage in humans: a review of quantitative data.</article-title>
            <source>Mutagenesis</source>
            <year>2004</year>
            <month>May</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>169</fpage>
            <page-range>169-85</page-range>
            <pub-id pub-id-type="pmid">15123782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Resnick</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Gordenin</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The choice of nucleotide inserted opposite abasic sites formed within chromosomal DNA reveals the polymerase activities participating in translesion DNA synthesis.</article-title>
            <source>DNA Repair (Amst)</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>11</issue>
            <fpage>878</fpage>
            <page-range>878-89</page-range>
            <pub-id pub-id-type="pmid">23988736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Mutagenic repair of DNA interstrand crosslinks.</article-title>
            <source>Environ Mol Mutagen</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>493</fpage>
            <page-range>493-9</page-range>
            <pub-id pub-id-type="pmid">20209624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ranzani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Annunziato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Montini</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Cancer gene discovery: exploiting insertional mutagenesis.</article-title>
            <source>Mol Cancer Res</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>1141</fpage>
            <page-range>1141-58</page-range>
            <pub-id pub-id-type="pmid">23928056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlson</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Upadhyaya</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hecht</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>A General Method for Detecting Nitrosamide Formation in the In Vitro Metabolism of Nitrosamines by Cytochrome P450s.</article-title>
            <source>J Vis Exp</source>
            <year>2017</year>
            <month>Sep</month>
            <day>25</day>
            <issue>127</issue>
            <pub-id pub-id-type="pmid">28994777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ling</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Approaches to DNA mutagenesis: an overview.</article-title>
            <source>Anal Biochem</source>
            <year>1997</year>
            <month>Dec</month>
            <day>15</day>
            <volume>254</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-78</page-range>
            <pub-id pub-id-type="pmid">9417773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Site-directed mutagenesis.</article-title>
            <source>Methods Enzymol</source>
            <year>2013</year>
            <volume>529</volume>
            <fpage>241</fpage>
            <page-range>241-8</page-range>
            <pub-id pub-id-type="pmid">24011050</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Behjati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tarpey</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>What is next generation sequencing?</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>98</volume>
            <issue>6</issue>
            <fpage>236</fpage>
            <page-range>236-8</page-range>
            <pub-id pub-id-type="pmid">23986538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stottmann</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beier</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>ENU Mutagenesis in the Mouse.</article-title>
            <source>Curr Protoc Hum Genet</source>
            <year>2014</year>
            <month>Jul</month>
            <day>14</day>
            <volume>82</volume>
            <fpage>15.4.1</fpage>
            <page-range>15.4.1-15.4.10</page-range>
            <pub-id pub-id-type="pmid">25042716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hryhorowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lipi&#x00144;ski</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeyland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>S&#x00142;omski</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>CRISPR/Cas9 Immune System as a Tool for Genome Engineering.</article-title>
            <source>Arch Immunol Ther Exp (Warsz)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>233</fpage>
            <page-range>233-240</page-range>
            <pub-id pub-id-type="pmid">27699445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hegazy</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Youns</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>TALENs Construction: Slowly but Surely.</article-title>
            <source>Asian Pac J Cancer Prev</source>
            <year>2016</year>
            <volume>17</volume>
            <issue>7</issue>
            <fpage>3329</fpage>
            <page-range>3329-34</page-range>
            <pub-id pub-id-type="pmid">27509972</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jabalameli</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Zahednasab</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Karimi-Moghaddam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jabalameli</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Zinc finger nuclease technology: advances and obstacles in modelling and treating genetic disorders.</article-title>
            <source>Gene</source>
            <year>2015</year>
            <month>Mar</month>
            <day>01</day>
            <volume>558</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">25536166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basu</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>DNA Damage, Mutagenesis and Cancer.</article-title>
            <source>Int J Mol Sci</source>
            <year>2018</year>
            <month>Mar</month>
            <day>23</day>
            <volume>19</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">29570697</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tomasetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vogelstein</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention.</article-title>
            <source>Science</source>
            <year>2017</year>
            <month>Mar</month>
            <day>24</day>
            <volume>355</volume>
            <issue>6331</issue>
            <fpage>1330</fpage>
            <page-range>1330-1334</page-range>
            <pub-id pub-id-type="pmid">28336671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Andreotti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Lerro</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Koutros</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hartge</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alavanja</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Sandler</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Tobacco Use and Cancer Risk in the Agricultural Health Study.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2017</year>
            <month>May</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>769</fpage>
            <page-range>769-778</page-range>
            <pub-id pub-id-type="pmid">28035020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarasin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bounacer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lepage</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schlumberger</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of mutagenesis in mammalian cells. Application to human thyroid tumours.</article-title>
            <source>C R Acad Sci III</source>
            <year>1999</year>
            <season>Feb-Mar</season>
            <volume>322</volume>
            <issue>2-3</issue>
            <fpage>143</fpage>
            <page-range>143-9</page-range>
            <pub-id pub-id-type="pmid">10196666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szikriszt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>P&#x000f3;ti</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>Pipek</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Krzystanek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kanu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moln&#x000e1;r</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ribli</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szeltner</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Tusn&#x000e1;dy</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Csabai</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Szallasi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Swanton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sz&#x000fc;ts</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive survey of the mutagenic impact of common cancer cytotoxics.</article-title>
            <source>Genome Biol</source>
            <year>2016</year>
            <month>May</month>
            <day>09</day>
            <volume>17</volume>
            <fpage>99</fpage>
            <pub-id pub-id-type="pmid">27161042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Naik</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Haywood</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell trait diagnosis: clinical and social implications.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2015</year>
            <volume>2015</volume>
            <issue>1</issue>
            <fpage>160</fpage>
            <page-range>160-7</page-range>
            <pub-id pub-id-type="pmid">26637716</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meremikwu</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Okomo</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Sickle cell disease.</article-title>
            <source>BMJ Clin Evid</source>
            <year>2016</year>
            <month>Jan</month>
            <day>22</day>
            <volume>2016</volume>
            <pub-id pub-id-type="pmid">26808098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Munita</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Arias</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of Antibiotic Resistance.</article-title>
            <source>Microbiol Spectr</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">27227291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Phelan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Francisco</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Pain</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Genome-wide mutagenesis and multi-drug resistance in American trypanosomes induced by the front-line drug benznidazole.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <day>31</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>14407</fpage>
            <pub-id pub-id-type="pmid">29089615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smits</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bolton</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Funari</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boyden</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Prysak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Merriman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Bonaf&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Superti-Furga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ikegawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Krakow</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Kirchhausen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Warman</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Beier</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Lethal skeletal dysplasia in mice and humans lacking the golgin GMAP-210.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Jan</month>
            <day>21</day>
            <volume>362</volume>
            <issue>3</issue>
            <fpage>206</fpage>
            <page-range>206-16</page-range>
            <pub-id pub-id-type="pmid">20089971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Gene mutation-based and specific therapies in precision medicine.</article-title>
            <source>J Cell Mol Med</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>577</fpage>
            <page-range>577-80</page-range>
            <pub-id pub-id-type="pmid">26994883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25408.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Redman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>What is CRISPR/Cas9?</article-title>
            <source>Arch Dis Child Educ Pract Ed</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-5</page-range>
            <pub-id pub-id-type="pmid">27059283</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
